Description

• Arise Ventures primarily invests at the pre-seed and seed stages, often serving as one of the first institutional investors.
  
  
• The firm is designed to support founders as they transition from concept or early validation into scalable healthcare businesses.
  
  

• Arise Ventures may selectively participate in Series A rounds, particularly for portfolio companies demonstrating strong clinical, regulatory, or commercial progress.
  
  

• Typical initial investments are generally in the ~$250K–$1M range, depending on:
  
  
  • Company stage and capital needs
    
    
  • Scientific or technical maturity
    
    
  • Syndicate composition
    
    

• Arise Ventures does not publicly disclose a fixed ownership target.
  
  
• Equity stakes are negotiated deal-by-deal, based on valuation, round size, and risk profile.
  
  
• Ownership is typically minority and non-controlling.
  
  

• Given early-stage valuations in healthcare and life sciences, Arise Ventures’ ownership in an initial round often falls in the single-digit to low-teens percentage range, but this varies materially by deal structure and capital intensity.
  
  

• Investments are typically structured using standard healthcare venture instruments, including:
  
  
  • Priced preferred equity (Seed / Series A)
    
    
  • Convertible notes or SAFEs (less common in capital-intensive biotech, more common in digital health)
    
    
• Deals may include milestone-based considerations, especially in therapeutics, diagnostics, or regulated medical products.
  
  

• Arise Ventures reviews opportunities primarily through:
  
  
  • Warm introductions from founders, operators, clinicians, and co-investors
    
    
  • Direct founder outreach via its website or professional network
    
    
• There is no publicly advertised accelerator-style application portal.
  
  

• Initial conversations focus on:
  
  
  • Scientific or clinical rationale
    
    
  • Market need and differentiation
    
    
  • Founding team expertise and execution capability
    
    

Eligibility

• Healthcare and life sciences, including:
  
  
  • Digital health & health IT
    
    
  • Biotech & therapeutics
    
    
  • Medical devices & diagnostics
    
    
  • Healthcare services & care delivery innovation
    
    

• Primarily United States-based companies, with flexibility depending on regulatory strategy and market focus.
  
  

• Pre-seed and seed-stage companies with:
  
  
  • Clear clinical or technical validation path
    
    
  • Defined regulatory strategy (where applicable)
    
    
  • Strong early evidence of demand or unmet need
    
    

• Strong emphasis on women founders and diverse leadership, particularly teams with deep domain, clinical, or scientific expertise.
  
  

Process

1. Initial Screening: Review of science, product concept, and founding team credentials.
   
   
2. Partner Review: Internal diligence on clinical relevance, market size, and investment thesis.
   
   
3. Expert Input: Use of advisors or external experts for scientific, clinical, or regulatory diligence.
   
   
4. Founder Meetings: Deep dives into roadmap, milestones, and capital strategy.
   
   
5. Investment Decision: Terms negotiated; capital deployed following consensus.

What an Applicant can Obtain